The European Commission’s Pharmaceutical Sector Inquiry raised significant concerns regarding so-called “reverse payment” patent settlement agreements. In this article, CRA describes the types of information or economic evidence that might facilitate evaluation of the competitive aspects of these settlements. To read the article, click here:
What happens when AI sets wages
The authors fed 60,000 freelancer profiles into eight widely used LLMs, asking each model to recommend an hourly rate. From hourly wage setting to testing for...